You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In response to BD's patent suit, 10x alleged BD's single-cell products infringe its own patents. 10x also asked the judge to dismiss BD's lawsuit.
The index, which slightly underperformed the Dow Jones, had a smaller loss in August than in the previous month.
Spurred to develop new microfluidic chip technology, 10x told customers not to worry about the transition but told a court there would be "guaranteed hitches."
The case, which was originally being fought between Enzo and Hologic, was decided in favor of Becton Dickinson, Hologic's co-plaintiff.
In addition to the $24 million jury verdict, 10x must pay an additional $8.3 million in damages and $2.2 million in interest. It has appealed the case.
Among the claims, NeuMoDx has alleged that BD was kept up to date on the firm's technology as it was developed and that one of the patents was duplicitously expanded by BD.
The Broad Institute called UC's new legal strategy "deeply unfortunate" and called on the university to "move beyond litigation."
As MPEG LA tries to complete its larger CRISPR IP patent pool, smaller license agreements continue and a mini-pool has emerged between key players.
A federal judge upheld a $24 million jury award to Bio-Rad, while a trade court judge said Bio-Rad imported microfluidics that infringed 10x patents.
Guardant told a federal judge that it believes Foundation Medicine and Personal Genome Diagnostics are coordinating to invalidate its patents.
An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.
The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.
CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.
In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.